• Anteris raises $320 million in combined underwritten offering and private placement
• Proceeds to support DurAVR® THV global pivotal trial and manufacturing expansion
• Covidien Group S.à r.l. invests $90 million in private placement

Anteris Technologies Global Corp. (Nasdaq: AVR, ASX: AVR) announced that it has entered into an Underwriting Agreement to raise approximately $230 million through a public offering of 40 million shares of common stock at $5.75 per share. Additionally, the company entered into a Stock Purchase Agreement with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc, to raise $90 million through a private placement of 15.7 million shares at $5.75 per share. The combined gross proceeds of $320 million will be used to support the next stage of growth and advance execution of the company's clinical strategy, including ongoing recruitment and study execution of the DurAVR® Transcatheter Heart Valve (DurAVR® THV) global pivotal trial for patients with severe aortic stenosis, as well as expansion of manufacturing capabilities. A portion of the proceeds will also fund ongoing research and development for v2vmedtech, Inc., with the balance allocated to working capital and other general corporate purposes. As part of the transaction, Covidien Group S.à r.l. will receive certain rights, including participation rights, transfer restrictions, a collaboration agreement, a standstill provision, a voting agreement, and a board observer right.

The company estimates the gross proceeds from the underwritten offering and private placement will be approximately $320 million, which will be used to support the DurAVR® THV global pivotal trial and expansion of manufacturing capabilities.